European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Aybintio, bevacizumab, Date of authorisation: 19/08/2020, Revision: 13, Status: Authorised

Submitted by Anonymous (not verified) on 11 September 2026 - 16:00

Human medicines European public assessment report (EPAR): Aybintio, bevacizumab, Date of authorisation: 19/08/2020, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Date of authorisation: 14/02/2022, Revision: 11, Status: Authorised

Submitted by Anonymous (not verified) on 11 September 2026 - 15:45

Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Date of authorisation: 14/02/2022, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Vyloy, zolbetuximab, Date of authorisation: 19/09/2024, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 11 September 2026 - 15:33

Human medicines European public assessment report (EPAR): Vyloy, zolbetuximab, Date of authorisation: 19/09/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Repaglinide Accord, repaglinide, Date of authorisation: 22/12/2011, Revision: 8, Status: Withdrawn

Submitted by Anonymous (not verified) on 11 September 2026 - 15:25

Human medicines European public assessment report (EPAR): Repaglinide Accord, repaglinide, Date of authorisation: 22/12/2011, Revision: 8, Status: Withdrawn

Human medicines European public assessment report (EPAR): Bilprevda, denosumab, Date of authorisation: 17/09/2025, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 11 September 2026 - 15:11

Human medicines European public assessment report (EPAR): Bilprevda, denosumab, Date of authorisation: 17/09/2025, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Emgality, galcanezumab, Date of authorisation: 14/11/2018, Revision: 15, Status: Authorised

Submitted by Anonymous (not verified) on 11 September 2026 - 15:03

Human medicines European public assessment report (EPAR): Emgality, galcanezumab, Date of authorisation: 14/11/2018, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Lynkuet, elinzanetant, Date of authorisation: 17/11/2025, Revision: 2, Status: Authorised

Submitted by Anonymous (not verified) on 11 September 2026 - 14:54

Human medicines European public assessment report (EPAR): Lynkuet, elinzanetant, Date of authorisation: 17/11/2025, Revision: 2, Status: Authorised

Veterinary medicines European public assessment report (EPAR): AviGate S. Typhimurium, Salmonella enterica, subsp. enterica, serovar Typhimurium, strain Nal2/Rif9/Rtt, Live, Status: Opinion

Submitted by Anonymous (not verified) on 11 September 2026 - 12:00

Veterinary medicines European public assessment report (EPAR): AviGate S. Typhimurium, Salmonella enterica, subsp. enterica, serovar Typhimurium, strain Nal2/Rif9/Rtt, Live, Status: Opinion

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness